Muscarinic acetylcholine receptors (mAChRs) are central to the modulation of neurotransmission in the human brain and are emerging as promising targets in the management of neuropsychiatric disorders.

In the December 2 Nature Chemical Biology, researchers led by Jeffrey Conn at Vanderbilt University, Nashville, Tennessee, report that they have developed a small molecule that not only boosts the ...

Research at Monash University has led to the identification of structurally novel muscarinic acetylcholine receptor (mAChR) positive allosteric modulators (PAMs) with potential utility in treating ...

Acetylcholine "conductors" in the striatum directly trigger serotonin release, offering new insights into the origins of OCD and chemical imbalances.

Cocaine, opioids, and other drugs of abuse disrupt the brain's reward system, often shifting users' priorities to obtaining more drug above all else. For people battling addiction, this persistent ...

The fine balance between potency and selectivity that looms large in drug development has long stymied efforts to target the M1 muscarinic acetylcholine receptor (mAChR) for treatment of Alzheimer ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

More than 60% of complement inhibitor–naive patients with acetylcholine receptor–positive generalized myasthenia gravis (MG) in diverse clinical populations had a clinically meaningful reduction in MG ...

11C-Methionine positron emission tomography as an early predictor of outcome in bone and soft tissue sarcomas treated by carbon ion radiotherapy No significant financial relationships to disclose.

ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in ...